Spleen-Kidney Supplementing Formula Alleviates Renal Fibrosis in Diabetic Rats via TGF-β1-miR-21-PTEN Signaling Pathway

Figure 2

SKSF improved BUN, UREA, UA, CCR, KW/BW, and 24-hour urine protein in T2DM rats. (a) BUN, (b) UA, (c) Urea, (d) CCR, (e) KW/BW, (f) 24-hour urine protein. Data were expressed as mean ± SD, n =10 rats per group. N, normal group; M, model group; Met, metformin group; SKSF-l, Spleen-Kidney Supplementing Formula group at a low dose; SKSF-m, Spleen-Kidney Supplementing Formula group at a medium dose; SKSF-h, Spleen-Kidney Supplementing Formula group at a high dose. ^∗P < 0.05, ^∗∗P < 0.01 compared with model group.

(a)

(b)

(c)

(d)

(e)

(f)